Previous 10 | Next 10 |
AAWW, ACLS, ACRE, AGIO, AMRN, AMRX, ATH, ATY, AUPH, AUTL, AVA, BCRX, BDC, BDSI, BGCP, BIP, OTCPK:BMWYY, BR, BRSP, BWA, CDW, CIM, CIO, CLH, CLVS, CPRI, CRL, CRTO, CSTE, CTRA, CVE, CVS, CWH, DFIN, DISCA, OTCQX:DLAKF, OTCPK:DNNGY, DNOW, EAT, EMR, ES, ETR, EVRG, EVRI, EXC, EXPI, EYPT, FDP, FUN, F...
MORRISVILLE, N.C., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2021 financial results on Wednesday, November 3rd, 2021, prior to its earnings call at 8:00 a.m. ET...
ObsEva (NASDAQ:OBSV) announces a strategic relationship with Syneos Health (NASDAQ:SYNH) to commercialize linzagolix. Linzagolix is an oral GnRH receptor antagonist indicated for the treatment of uterine fibroids. ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide ...
MORRISVILLE, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the acquisition of RxDataScience , a leading healthcare-focused data analytics, data management and artificial...
MORRISVILLE, N.C., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the acquisition of StudyKIK , a leading technology-enabled clinical trial recruitment and retention company. ...
MORRISVILLE, N.C. and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Ride Health to offer non-emergency medical transportati...
– Company planning for three potential New Drug Application (NDA) filings in three years with the first submission expected in Q3 2022 for lead program SB206 in molluscum contagiosum – – Late-stage product candidate, SB204 for the treatment of acne...
I will recap events YTD for Idorsia. A status of pending results expected by the end of the year-2021. My continued support for Idorsia will be explained to my readers. For further details see: Idorsia: The Clock Is Ticking For The Countdown
Shares of Syneos Health Inc. (NASDAQ:SYNH) traded at a new 52-week high today of $93.93. So far today approximately 121,000 shares have been exchanged, as compared to an average 30-day volume of 623,000 shares. Syneos Health Inc. share prices have moved between a 52-week high of $93.93 a...
MORRISVILLE, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Alistair Macdonald and Chief Financial Officer Jason Meggs are scheduled to present a...
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...